December 5, 2016 / 12:27 PM / 8 months ago

BRIEF-VBL therapeutics announces positive DSMC review in phase 3 globe trial investigating VB-111 in RGBM

1 Min Read

Dec 5 (Reuters) - Vascular Biogenics Ltd -

* VBL therapeutics announces positive DSMC review in phase 3 globe trial investigating VB-111 in RGBM

* Committee reviewed globe safety data and did not find any adverse events that would be cause for concern

* Continue to expect full enrollment in globe study before year-end, with event-driven interim analysis expected sometime in mid-2017

* Full trial results for VB-111 expected in early 2018

* Says data safety monitoring committe recommended that study on VB-111 continue as planned Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below